188 related articles for article (PubMed ID: 9351975)
1. Mitindomide is a catalytic inhibitor of DNA topoisomerase II that acts at the bisdioxopiperazine binding site.
Hasinoff BB; Creighton AM; Kozlowska H; Thampatty P; Allan WP; Yalowich JC
Mol Pharmacol; 1997 Nov; 52(5):839-45. PubMed ID: 9351975
[TBL] [Abstract][Full Text] [Related]
2. Characterization of a Chinese hamster ovary cell line with acquired resistance to the bisdioxopiperazine dexrazoxane (ICRF-187) catalytic inhibitor of topoisomerase II.
Hasinoff BB; Kuschak TI; Creighton AM; Fattman CL; Allan WP; Thampatty P; Yalowich JC
Biochem Pharmacol; 1997 Jun; 53(12):1843-53. PubMed ID: 9256159
[TBL] [Abstract][Full Text] [Related]
3. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.
Sehested M; Wessel I; Jensen LH; Holm B; Oliveri RS; Kenwrick S; Creighton AM; Nitiss JL; Jensen PB
Cancer Res; 1998 Apr; 58(7):1460-8. PubMed ID: 9537249
[TBL] [Abstract][Full Text] [Related]
4. A QSAR study that compares the ability of bisdioxopiperazine analogs of the doxorubicin cardioprotective agent dexrazoxane (ICRF-187) to protect myocytes with DNA topoisomerase II inhibition.
Hasinoff BB; Patel D; Wu X
Toxicol Appl Pharmacol; 2020 Jul; 399():115038. PubMed ID: 32417440
[TBL] [Abstract][Full Text] [Related]
5. Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the alpha isoform.
Wessel I; Jensen LH; Jensen PB; Falck J; Rose A; Roerth M; Nitiss JL; Sehested M
Cancer Res; 1999 Jul; 59(14):3442-50. PubMed ID: 10416608
[TBL] [Abstract][Full Text] [Related]
6. A QSAR study comparing the cytotoxicity and DNA topoisomerase II inhibitory effects of bisdioxopiperazine analogs of ICRF-187 (dexrazoxane).
Hasinoff BB; Kuschak TI; Yalowich JC; Creighton AM
Biochem Pharmacol; 1995 Sep; 50(7):953-8. PubMed ID: 7575679
[TBL] [Abstract][Full Text] [Related]
7. The catalytic DNA topoisomerase II inhibitor dexrazoxane (ICRF-187) induces endopolyploidy in Chinese hamster ovary cells.
Hasinoff BB; Abram ME; Chee GL; Huebner E; Byard EH; Barnabé N; Ferrans VJ; Yu ZX; Yalowich JC
J Pharmacol Exp Ther; 2000 Nov; 295(2):474-83. PubMed ID: 11046078
[TBL] [Abstract][Full Text] [Related]
8. The cardioprotective and DNA topoisomerase II inhibitory agent dexrazoxane (ICRF-187) antagonizes camptothecin-mediated growth inhibition of Chinese hamster ovary cells by inhibition of DNA synthesis.
Hasinoff BB; Chee GL; Thampatty P; Allan WP; Yalowich JC
Anticancer Drugs; 1999 Jan; 10(1):47-54. PubMed ID: 10194547
[TBL] [Abstract][Full Text] [Related]
9. Probing the role of linker substituents in bisdioxopiperazine analogs for activity against wild-type and mutant human topoisomerase II alpha.
Renodon-Cornière A; Sørensen TK; Jensen PB; Nitiss JL; Søkilde B; Sehested M; Jensen LH
Mol Pharmacol; 2003 May; 63(5):1159-68. PubMed ID: 12695544
[TBL] [Abstract][Full Text] [Related]
10. The one-ring open hydrolysis intermediates of the cardioprotective agent dexrazoxane (ICRF-187) do not inhibit the growth of Chinese hamster ovary cells or the catalytic activity of DNA topoisomerase II.
Hasinoff BB; Kuschak TI; Fattman CL; Yalowich JC
Anticancer Drugs; 1998 Jun; 9(5):465-71. PubMed ID: 9660545
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and characterization of the biological activity of the cisplatin analogs, cis-PtCl(2)(dexrazoxane) and cis-PtCl(2)(levrazoxane), of the topoisomerase II inhibitors dexrazoxane (ICRF-187) and levrazoxane (ICRF-186).
Hasinoff BB; Wu X; Yang Y
J Inorg Biochem; 2004 Apr; 98(4):616-24. PubMed ID: 15041241
[TBL] [Abstract][Full Text] [Related]
12. Characterisation of cytotoxicity and DNA damage induced by the topoisomerase II-directed bisdioxopiperazine anti-cancer agent ICRF-187 (dexrazoxane) in yeast and mammalian cells.
Jensen LH; Dejligbjerg M; Hansen LT; Grauslund M; Jensen PB; Sehested M
BMC Pharmacol; 2004 Dec; 4():31. PubMed ID: 15575955
[TBL] [Abstract][Full Text] [Related]
13. Collateral sensitivity to the bisdioxopiperazine dexrazoxane (ICRF-187) in etoposide (VP-16)-resistant human leukemia K562 cells.
Fattman CL; Allan WP; Hasinoff BB; Yalowich JC
Biochem Pharmacol; 1996 Aug; 52(4):635-42. PubMed ID: 8759037
[TBL] [Abstract][Full Text] [Related]
14. The catalytic DNA topoisomerase II inhibitor dexrazoxane (ICRF-187) induces differentiation and apoptosis in human leukemia K562 cells.
Hasinoff BB; Abram ME; Barnabé N; Khélifa T; Allan WP; Yalowich JC
Mol Pharmacol; 2001 Mar; 59(3):453-61. PubMed ID: 11179439
[TBL] [Abstract][Full Text] [Related]
15. Analysis of bisdioxopiperazine dexrazoxane binding to human DNA topoisomerase II alpha: decreased binding as a mechanism of drug resistance.
Renodon-Cornière A; Jensen LH; Nitiss JL; Jensen PB; Sehested M
Biochemistry; 2003 Aug; 42(32):9749-54. PubMed ID: 12911317
[TBL] [Abstract][Full Text] [Related]
16. Selection of human leukemic CEM cells for resistance to the DNA topoisomerase II catalytic inhibitor ICRF-187 results in increased levels of topoisomerase IIalpha and altered G(2)/M checkpoint and apoptotic responses.
Morgan SE; Cadena RS; Raimondi SC; Beck WT
Mol Pharmacol; 2000 Feb; 57(2):296-307. PubMed ID: 10648639
[TBL] [Abstract][Full Text] [Related]
17. Mapping of DNA topoisomerase II poisons (etoposide, clerocidin) and catalytic inhibitors (aclarubicin, ICRF-187) to four distinct steps in the topoisomerase II catalytic cycle.
Sehested M; Jensen PB
Biochem Pharmacol; 1996 Apr; 51(7):879-86. PubMed ID: 8651936
[TBL] [Abstract][Full Text] [Related]
18. Attenuated topoisomerase II content directly correlates with a low level of drug resistance in a Chinese hamster ovary cell line.
Webb CD; Latham MD; Lock RB; Sullivan DM
Cancer Res; 1991 Dec; 51(24):6543-9. PubMed ID: 1660341
[TBL] [Abstract][Full Text] [Related]
19. Proliferation-dependent topoisomerase II content as a determinant of antineoplastic drug action in human, mouse, and Chinese hamster ovary cells.
Sullivan DM; Latham MD; Ross WE
Cancer Res; 1987 Aug; 47(15):3973-9. PubMed ID: 3038304
[TBL] [Abstract][Full Text] [Related]
20. The effect of dexrazoxane (ICRF-187) on doxorubicin- and daunorubicin-mediated growth inhibition of Chinese hamster ovary cells.
Hasinoff BB; Yalowich JC; Ling Y; Buss JL
Anticancer Drugs; 1996 Jul; 7(5):558-67. PubMed ID: 8862724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]